[go: up one dir, main page]

MX2012010114A - Formulaciones concentradas de proteina y usos de las mismas. - Google Patents

Formulaciones concentradas de proteina y usos de las mismas.

Info

Publication number
MX2012010114A
MX2012010114A MX2012010114A MX2012010114A MX2012010114A MX 2012010114 A MX2012010114 A MX 2012010114A MX 2012010114 A MX2012010114 A MX 2012010114A MX 2012010114 A MX2012010114 A MX 2012010114A MX 2012010114 A MX2012010114 A MX 2012010114A
Authority
MX
Mexico
Prior art keywords
formulations
concentrated protein
protein formulations
high concentration
protein drug
Prior art date
Application number
MX2012010114A
Other languages
English (en)
Other versions
MX347504B (es
Inventor
Tracy T Chen
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of MX2012010114A publication Critical patent/MX2012010114A/es
Publication of MX347504B publication Critical patent/MX347504B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen formulaciones hipotónicas, de baja viscosidad que contienen una o más proteínas, por ejemplo, anticuerpos, a alta concentración, usos de las formulaciones, y artículos de elaboración. En particular, las formulaciones son útiles y benéficas para la administración o suministro subcutáneo de una alta concentración de un fármaco de proteína, tal como un anticuerpo, a un sujeto que padece una enfermedad o condición que se puede tratar con el fármaco de proteína.
MX2012010114A 2010-03-01 2011-03-01 Formulaciones concentradas de proteina y usos de las mismas. MX347504B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33919110P 2010-03-01 2010-03-01
PCT/US2011/026647 WO2011109365A2 (en) 2010-03-01 2011-03-01 Concentrated protein formulations and uses thereof

Publications (2)

Publication Number Publication Date
MX2012010114A true MX2012010114A (es) 2013-01-29
MX347504B MX347504B (es) 2017-04-28

Family

ID=44542798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010114A MX347504B (es) 2010-03-01 2011-03-01 Formulaciones concentradas de proteina y usos de las mismas.

Country Status (15)

Country Link
US (2) US9956165B2 (es)
EP (1) EP2542221A4 (es)
JP (2) JP5937523B2 (es)
KR (1) KR101853981B1 (es)
CN (2) CN102946861B (es)
AU (2) AU2011223805B2 (es)
BR (1) BR112012022223B1 (es)
CA (1) CA2794929C (es)
IL (1) IL221748B (es)
MX (1) MX347504B (es)
NZ (1) NZ602685A (es)
RU (1) RU2626512C2 (es)
SG (1) SG184355A1 (es)
WO (1) WO2011109365A2 (es)
ZA (1) ZA201207331B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946861B (zh) * 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
EP3904390A1 (en) 2014-08-20 2021-11-03 CytoDyn Inc. Hiv antibody therapy as treatment substitute
PH12017500370B1 (en) 2014-09-03 2023-12-06 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
CN106999510B (zh) 2014-10-01 2021-04-30 伊格尔生物制品有限公司 含有粘度降低剂的多糖和核酸制剂
MX2017004975A (es) * 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
EP3207936B1 (en) 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
EP3250596A1 (en) 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
HRP20192222T1 (hr) * 2015-02-09 2020-02-21 UCB Biopharma SRL Farmaceutska formulacija koja sadrži antitijelo
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
CN110366429B (zh) * 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
AR112403A1 (es) * 2017-08-03 2019-10-23 Jazz Pharmaceuticals Ireland Ltd Formulaciones de ácidos nucleicos altamente concentradas
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US20190085086A1 (en) 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
IL318714A (en) 2018-05-10 2025-03-01 Regeneron Pharma Formulations that include high concentrations of VEGF receptor fusion protein
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
WO2020216847A1 (en) * 2019-04-23 2020-10-29 Sanofi Stable, low-viscosity antibody formulations and uses thereof
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2021214759A1 (en) * 2020-04-22 2021-10-28 Chemomab Ltd. Method of treatment using anti-ccl24 antibody
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
CN116034985B (zh) * 2022-12-12 2025-09-16 武汉呵尔医疗科技发展有限公司 一种细胞保护液、hpv e6/e7质控片的制备方法及应用
WO2025089468A1 (ko) * 2023-10-27 2025-05-01 주식회사 엔솔바이오사이언스 펩타이드 함유 액상제제 및 그 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CN1292655C (zh) * 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1478738B1 (en) 2002-02-22 2008-11-12 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
PT1478394E (pt) * 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
CA2519408C (en) * 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
CN101309703A (zh) * 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
HUE033949T2 (hu) * 2005-11-01 2018-01-29 Wyeth Llc Nátrium klorid oldat gyógyszer újraoldására vagy hígítására
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
WO2008051363A2 (en) * 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
CN102946861B (zh) * 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途

Also Published As

Publication number Publication date
US20180263898A1 (en) 2018-09-20
ZA201207331B (en) 2014-07-30
IL221748B (en) 2019-09-26
KR101853981B1 (ko) 2018-05-02
CN105521491B (zh) 2020-03-24
AU2011223805A1 (en) 2012-10-25
CN105521491A (zh) 2016-04-27
WO2011109365A3 (en) 2012-01-05
KR20130010898A (ko) 2013-01-29
CA2794929C (en) 2018-06-05
WO2011109365A2 (en) 2011-09-09
AU2016200495B2 (en) 2017-11-09
JP2013521296A (ja) 2013-06-10
US11571383B2 (en) 2023-02-07
EP2542221A2 (en) 2013-01-09
BR112012022223A8 (pt) 2017-12-05
BR112012022223B1 (pt) 2022-08-09
JP2016193911A (ja) 2016-11-17
AU2011223805B2 (en) 2015-10-29
NZ602685A (en) 2014-10-31
BR112012022223A2 (pt) 2016-07-05
US20130216525A1 (en) 2013-08-22
CA2794929A1 (en) 2011-09-09
SG184355A1 (en) 2012-11-29
EP2542221A4 (en) 2013-10-23
US9956165B2 (en) 2018-05-01
RU2012141655A (ru) 2014-04-10
AU2016200495A1 (en) 2016-02-18
CN102946861B (zh) 2016-01-20
JP5937523B2 (ja) 2016-06-22
HK1223835A1 (zh) 2017-08-11
RU2626512C2 (ru) 2017-07-28
CN102946861A (zh) 2013-02-27
JP6229007B2 (ja) 2017-11-08
MX347504B (es) 2017-04-28

Similar Documents

Publication Publication Date Title
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
TN2014000431A1 (en) Antibody formulatoin
PH12019500517A1 (en) Long-acting formulations of insulins
PH12014502778A1 (en) Antibody formulation
MY188825A (en) High-concentration monoclonal antibody formulations
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2011104381A3 (en) Stable antibody containing compositions
AU2013334740A8 (en) Stable, low viscosity antibody formulation
WO2012076670A3 (en) Antibody formulation
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MY193913A (en) Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody
WO2014204988A3 (en) 5t4-targeted immunofusion molecule and methods
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
NZ702342A (en) Pharmaceutical formulation
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
MX348337B (es) Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
WO2011133894A3 (en) Protein drug formulations and packages
EA201270717A3 (ru) Лиофилизированный препарат атф и комплекса витаминов группы в и атф и комплекс витаминов группы в виде инъекций
JP2013505038A5 (es)
Ilyin et al. Gender education of pre-school children

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CYTODYN INC.

FG Grant or registration